Affiliation:
1. Universal College of Medical Sciences
2. Al-Ameen College of Pharmacy
3. Nargund College of Pharmacy
4. Prof. Ravindra Nikam College of Pharmacy
5. R. C. Patel Institute of Pharmaceutical Education and Research
Abstract
Abstract
Tuberculosis, colloquially referred to as TB, is a highly prevalent bacterial infection that persists as a substantial global health concern. The present article centers its attention on the comprehensive exploration of the synthesis, molecular docking, and molecular dynamic simulation investigations pertaining to substituted benzimidazole derivatives. Additionally, a meticulous assessment of their anti-TB activities is conducted. A series of twelve substituted benzimidazole derivatives (1–12) were successfully synthesized, employing a scaffold consisting of electron-withdrawing and electron-donating groups. The newly synthesized compounds were defined by their FT-IR, 1H-NMR, and Mass spectra. The Microplate Alamar Blue Assay (MABA) was used to evaluate the anti-mycobacterial activity of synthesized compound against Mycobacterium tuberculosis (Mtb). Compounds 7 (MIC = 0.8 g/ml) and 8 (MIC = 0.8 g/ml) demonstrated exceptional potential to inhibit M. tuberculosis compared to the standard (Isoniazid). In addition, the synthesized compounds were docked with the Mtb KasA protein (PDB ID: 6P9K), and the results of molecular docking and molecular dynamic simulation confirmed the experimental results, as compounds 7 and 8 exhibited the highest binding energy of -7.36 and − 7.17 kcal/mol, respectively. Both substances were safe for acute inhalation and cutaneous sensitization. These two compounds have the potential to be potent M. tuberculosis inhibitors.
Publisher
Research Square Platform LLC
Reference47 articles.
1. [[1] TM, Daniel JH, Bates, Downes KA (2014) History of Tuberculosis. In: Bloom BR (ed) in Tuberculosis. ASM Press, Washington, DC, USA, pp 13–24
2. WHO (2022) “” 2022. doi: https://www.who.int/publications/i/item/9789240061729
3. Cox HS, Morrow M, Deutschmann PW (2008) “Long term efficacy of DOTS regimens for tuberculosis: systematic review,” BMJ, vol. 336, no. 7642, pp. 484–487, Mar. doi: 10.1136/bmj.39463.640787.BE
4. Thapa S, Nargund SL, Biradar MS (2023) “Molecular Design and In-Silico Analysis of Trisubstituted Benzimidazole Derivatives as Ftsz Inhibitor,” J. Chem., vol. pp. 1–9, Mar. 2023, doi: 10.1155/2023/9307613
5. Silesky-Jiménez JI (2020) Tuberculosis Multidrug Resistance (MDR-TB). Highly Infectious Diseases in Critical Care. Springer International Publishing, Cham, pp 235–252
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献